Table 1 Representing the exosomal miRNAs in biological fluids as prognostic and diagnostic biomarkers and therapeutic targets in lung cancer
From: Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer
Exosomal miRNAs | Sample Type | Role | Mechanism of action | References |
|---|---|---|---|---|
miR-378 | Serum | Prognostic | Screening and management of NSCLC | Zhang et al. (2020) [32] |
miR-382 | Serum | Prognostic | Improved the accuracy of carcinoembryonic antigen (CEA) | Luo et al. (2021) [33] |
miR-1260b | Plasma | Prognostic | Promotes angiogenesis in HUVECs and metastasis of NSCLC | Kim et al. (2021) [34] |
miR-323-3p, miR-1468-3p, miR-5189-5p and miR-6513-5p | Plasma | Prognostic | Distinguishing osimertinib-resistant from osimertinib-sensitive NSCLC patients | Janpipatkul et al. (2021) [35] |
miR-486-5p and miR-146a-5p | Serum | Diagnostic | Improvement of early diagnosis for NSCLC. | Wu et al. (2020) [36] |
miR-184, miR-3913-5p | Blood | Diagnostic | Indicate osimertinib resistance. | Li et al. (2021) [37] |
miR-125b-5p and miR-5684 | Serum | Diagnostic and Prognostic | Associated with metastasis, chemotherapeutic effect and survival | Zhang et al. (2020) [38] |
miR-620 | Serum | Diagnostic and Prognostic | Chemotherapeutic effect | Tang et al. (2020) [39] |
miR-1246 | Serum | Diagnostic and Prognostic | Associated with lymph node metastasis and TNM stage | Huang et al. (2020) [40] |
miR-96 | Plasma | Diagnostic and Prognostic | Radioresistant in NSCLC | Zheng et al. (2021) [41] |
miR-375-3p | Blood | Therapeutic target | monitoring metastasis and guiding clinical therapeutics of SCLC patients | Mao et al. (2021) [42] |
miR-433 | Plasma | Therapeutic target | inhibits tumorigenesis through incremental infiltration of CD4 and CD8 cells | Liu et al. (2021) [43] |